PULSAR - A Prospective study to evaluate the Utility of Low doses of the Statins Atorvastatin and Rosuvastatin.
Study identifier:4522IL/0102
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 6-week open-label, randomised, multicentre, phase IIIb, parallel-group study to compare the efficacy and safety of rosuvastatin (10 mg) with atorvastatin (20 mg) in subjects with hypercholesterolaemia and either a history of CHD or clinical evidence of CHD
Medical condition
hypercholesterolaemia
Phase
Phase 3
Healthy volunteers
No
Study drug
Rosuvastatin, Atorvastatin
Sex
All
Actual Enrollment
1000
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Nov 2003
Primary Completion Date: -
Study Completion Date: 01 Aug 2004
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Crestor Medical Science Director
AstraZeneca
